Navigation Links
Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies
Date:5/20/2013

SAN DIEGO, May 20, 2013 /PRNewswire/ -- Dr. Gerald Zon , noted scientist in the field of nucleic acid research, recently launched a new blog in conjunction with TriLink BioTechnologies. The blog, Zone In with Zon (zon.trilinkbiotech.com), focuses on what's trending in the field of nucleic acids. Blog posts include interviews with industry thought leaders, discussions of research presented at conferences and meetings, reviews of current publications and more.

Dr. Zon (PhD Princeton University 1971) developed automated synthesis of DNA analogs at the National Institutes of Health, and later at Applied Biosystems (ABI). In 1992 he co-founded ABI spin-off Lynx Therapeutics, an antisense company. He returned to ABI in 1999 to head DNA sequencing R&D, and then worked on novel methods for DNA sequencing as a Research Fellow at Life Technologies. In 2006, Dr. Zon was admitted as a Fellow of The Royal Society of Chemistry in the UK. At TriLink BioTechnologies since 2011, he is now Director of Business Development. Dr. Zon has published over 260 papers and patents, and is a longtime member of the Editorial Board for Analytical Biochemistry.

About TriLink
TriLink manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp™ PCR products for the diagnostic and OEM markets. In addition, custom chemistry, long RNA transcript synthesis and contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 50 scientists and other professionals. For more information about the firm and products, visit our web site at www.trilinkbiotech.com.

Contact:
Jerry Zon
gzon@trilinkbiotech.com


'/>"/>
SOURCE TriLink BioTechnologies
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
2. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
3. Jerry Adams Joins VIC Technology Venture Development Board of Directors
4. Market Access Expert Firm, PRMA Consulting, Launches Companion Diagnostics Handbook
5. J. Craig Venter Institutes Mobile Genomics Lab Launches First School Visits in San Diego County
6. Lisa Lorraine Reyes Muñoz, GeneCell International’s Physician Relation's Manager Launches Educational Meetings for General Public on Umbilical Cord Blood Stem Cells
7. Neogen launches comprehensive cattle genomic test
8. Marshfield Dentist Launches Groundbreaking Cavity Prevention Program That Can Lower Tooth Decay Rates by 74 Percent
9. Dentistry at Somerset Launches Ground Breaking Cavity Prevention Program That Can Lower Decay Rates by 74%
10. CellHealth Institute Launches New Cell Health Formula
11. Wysebridge Patent Bar Review Launches America Invents Act (AIA) Study Suite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an ... to find a better treatment for triple negative breast cancer ... France program. The YEi ... accelerator designed to help entrepreneurs grow their business in ... of eight American companies selected to complete an intensive one ...
(Date:2/16/2017)... Research and Markets has announced the addition ... to their offering. ... The study scope includes ... chassis organisms, synthetic cells, production systems), enabling technologies (DNA ... specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, agriculture) ...
(Date:2/16/2017)... Feb. 16, 2017 UCHealth ( Aurora, ... LungDirect for pulmonary nodule patient management. In addition to ... a spot on the lung, UCHealth looks to improve ... data entry. Stephanie Brown, RN , ... nodule patients with an Excel spreadsheet, which was extremely ...
(Date:2/16/2017)... Feb. 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... influenza study showed that aerosolized KL4 surfactant reduced ... well-established preclinical animal model. The Company believes that ... of evidence that supports the role of KL4 ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/21/2017)... 20, 2017 Research and Markets has announced ... report to their offering. ... The global voice recognition biometrics market to grow ... The report covers the present scenario and the growth prospects ... the market size, the report considers the revenue generated from the ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
Breaking Biology News(10 mins):